Related Experiment Video
Updated: Oct 7, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Personalizing Approaches to Management of HPV+ Oropharyngeal Cancer
1Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.
Abstract:
HPV+ oropharyngeal cancer represents a unique disease entity in the realm of head and neck cancer with distinct incidence and prevalence, pathogenesis, and treatment outcome. Management of this disease needs to be personalized in consideration of a combination of factors of both patient and disease characteristics. Overall outcomes in this patient population are excellent. Therefore, late side effects of treatment are gaining increasing importance and attention. Here we present a brief overview of personalized approaches for this patient population, illustrated by a discussion of several cases.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...